Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Patterns of Response and Progression to Immunotherapy.

Borcoman E, Nandikolla A, Long G, Goel S, Le Tourneau C.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):169-178. doi: 10.1200/EDBK_200643.

2.

Three-year results after radiotherapy for locally advanced sinonasal adenoid cystic carcinoma, using highly conformational radiotherapy techniques proton therapy and/or Tomotherapy.

Dautruche A, Bolle S, Feuvret L, Le Tourneau C, Jouffroy T, Goudjil F, Zefkili S, Nauraye C, Rodriguez J, Herman P, Calugaru V.

Cancer Radiother. 2018 Sep;22(5):411-416. doi: 10.1016/j.canrad.2017.11.015. Epub 2018 Jul 29.

PMID:
30064829
3.

First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer.

Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J.

Ann Oncol. 2018 Jul 28. doi: 10.1093/annonc/mdy244. [Epub ahead of print]

PMID:
30060061
4.

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.

Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X.

Oncotarget. 2018 May 8;9(35):23890-23899. doi: 10.18632/oncotarget.25156. eCollection 2018 May 8.

5.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M.

ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018.

6.

Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.

Outh-Gauer S, Alt M, Le Tourneau C, Augustin J, Broudin C, Gasne C, Denize T, Mirghani H, Fabre E, Ménard M, Scotte F, Tartour E, Badoual C.

Cancer Treat Rev. 2018 Apr;65:54-64. doi: 10.1016/j.ctrv.2018.02.008. Epub 2018 Mar 1. Review.

PMID:
29547766
7.

Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome.

Kamal M, Tarcic G, Dureau S, Edelheit O, Barbash Z, Lecerf C, Morel C, Miron B, Callens C, Servant N, Bieche I, Vidne M, Le Tourneau C.

Mol Oncol. 2018 May;12(5):594-601. doi: 10.1002/1878-0261.12180. Epub 2018 Mar 30.

8.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

PMID:
29462123
9.

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.

Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I.

Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11.

PMID:
29331751
10.

Precision medicine strategies in oncology: mixed approaches to matched therapies.

Borcoman E, Le Tourneau C.

Future Oncol. 2018 Jan;14(2):105-109. doi: 10.2217/fon-2017-0524. Epub 2017 Dec 11. No abstract available.

PMID:
29224361
11.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.

Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin MP, Alt M, Bahleda R, Varga A, Boetsch C, Franjkovic I, Heil F, Lahr A, Lechner K, Morel A, Nayak T, Rossomanno S, Smart K, Stubenrauch K, Krieter O.

Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. doi: 10.1158/1078-0432.CCR-17-1588. Epub 2017 Dec 7.

PMID:
29217526
12.

Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?

Ricci F, Le Tourneau C.

Chin Clin Oncol. 2018 Feb;7(1):3. doi: 10.21037/cco.2017.10.08. Epub 2017 Nov 6. No abstract available.

13.

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F.

Ann Oncol. 2018 Jan 1;29(1):30-35. doi: 10.1093/annonc/mdx707.

PMID:
29140430
14.

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A.

J Clin Oncol. 2017 Dec 20;35(36):4035-4041. doi: 10.1200/JCO.2017.74.5471. Epub 2017 Nov 2.

PMID:
29095678
15.

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03.

Fayette J, Guigay J, Le Tourneau C, Degardin M, Peyrade F, Neidhardt EM, Sablin MP, Even C, Orlandini F, Juzyna B, Bellera C.

Oncotarget. 2017 Mar 4;8(31):51830-51839. doi: 10.18632/oncotarget.15901. eCollection 2017 Aug 1.

16.

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR.

J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24.

PMID:
28837405
17.

Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing: A Solution for Transferring Integrated Pangenomic Studies into Routine Practice?

Garinet S, Néou M, de La Villéon B, Faillot S, Sakat J, Da Fonseca JP, Jouinot A, Le Tourneau C, Kamal M, Luscap-Rondof W, Boeva V, Gaujoux S, Vidaud M, Pasmant E, Letourneur F, Bertherat J, Assié G.

J Mol Diagn. 2017 Sep;19(5):776-787. doi: 10.1016/j.jmoldx.2017.06.005.

PMID:
28826610
18.

Patient-reported tolerability of adverse events in phase 1 trials.

Henon C, Lissa D, Paoletti X, Thibault C, Le Tourneau C, Lanoy E, Hollebecque A, Massard C, Soria JC, Postel-Vinay S.

ESMO Open. 2017 Jun 23;2(2):e000148. doi: 10.1136/esmoopen-2016-000148. eCollection 2017.

19.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
20.

NUT carcinoma in children and adults: A multicenter retrospective study.

Lemelle L, Pierron G, Fréneaux P, Huybrechts S, Spiegel A, Plantaz D, Julieron M, Dumoucel S, Italiano A, Millot F, Le Tourneau C, Leverger G, Chastagner P, Carton M, Orbach D.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26693. Epub 2017 Jun 23.

PMID:
28643357
21.

Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.

Borcoman E, Le Tourneau C.

Ther Adv Med Oncol. 2017 Jun;9(6):431-439. doi: 10.1177/1758834017708742. Epub 2017 May 8. Review.

22.

The SHIVA01 trial: what have we learned?

Le Tourneau C, Kamal M, Bièche I.

Pharmacogenomics. 2017 Jun;18(9):831-834. doi: 10.2217/pgs-2017-0062. Epub 2017 Jun 8. No abstract available.

23.

Optimizing drug development in oncology by clinical trial simulation: Why and how?

Gal J, Milano G, Ferrero JM, Saâda-Bouzid E, Viotti J, Chabaud S, Gougis P, Le Tourneau C, Schiappa R, Paquet A, Chamorey E.

Brief Bioinform. 2017 May 29. doi: 10.1093/bib/bbx055. [Epub ahead of print]

PMID:
28575140
24.

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C.

Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178.

PMID:
28419181
25.

First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.

Dieras V, Pop S, Berger F, Dujaric ME, Beuzeboc P, Escalup L, Bidard FC, Cottu PH, LE Tourneau C, Piperno-Neumann S, Laurence V, Robain M, Asselain B, Pierga JY.

Anticancer Res. 2017 Mar;37(3):1403-1407.

PMID:
28314310
26.

Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine.

Stoeklé HC, Mamzer-Bruneel MF, Frouart CH, Le Tourneau C, Laurent-Puig P, Vogt G, Hervé C.

Sci Eng Ethics. 2018 Feb;24(1):307-322. doi: 10.1007/s11948-017-9880-8. Epub 2017 Mar 9.

27.

[Cell cycle inhibitors in endocrine receptor positive breast cancer].

Sablin MP, Ricci F, Loirat D, Jobard A, Basse C, Romano E, Le Tourneau C, Dieras V.

Bull Cancer. 2017 Feb;104(2):114-122. doi: 10.1016/j.bulcan.2016.12.005. Epub 2017 Jan 23. French.

PMID:
28126188
28.

[Current events in immunotherapy for upper aerodigestive tract cancer].

Outh-Gauer S, Le Tourneau C, Broudin C, Scotte F, Roussel H, Hans S, Mandavit M, Tartour E, Badoual C.

Ann Pathol. 2017 Feb;37(1):79-89. doi: 10.1016/j.annpat.2016.12.013. Epub 2017 Jan 19. Review. French.

PMID:
28111039
29.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, Dieci MV, Kamal M, Diéras V, Gonçalves A, Ferrerro JM, Romieu G, Vanlemmens L, Mouret Reynier MA, Théry JC, Le Du F, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, André F.

PLoS Med. 2016 Dec 27;13(12):e1002201. doi: 10.1371/journal.pmed.1002201. eCollection 2016 Dec.

30.

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C.

Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666.

PMID:
27993804
31.

Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.

Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I, Bernard V, Fréneaux P, Michon J, Orbach D, Aerts I, Pacquement H, Bourdeaut F, Jiménez I, Thébaud E, Oudot C, Vérité C, Taque S, Owens C, Doz F, Le Tourneau C, Delattre O, Schleiermacher G.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26365. Epub 2016 Nov 29.

PMID:
27896933
32.

Targeted therapies: What have we learned from SHIVA?

Le Tourneau C, Kurzrock R.

Nat Rev Clin Oncol. 2016 Dec;13(12):719-720. doi: 10.1038/nrclinonc.2016.164. Epub 2016 Oct 11. Review. No abstract available.

PMID:
27725677
33.

Combinations of targeted therapies in human cancers.

Decaudin D, Le Tourneau C.

Aging (Albany NY). 2016 Oct 26;8(10):2258-2259. doi: 10.18632/aging.101085. No abstract available.

34.

Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study.

Brédart A, Bodson S, Le Tourneau C, Flahault C, Bonnetain F, Beaudeau A, Coquan E, Dolbeault S, Paoletti X.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12596. Epub 2016 Oct 12.

PMID:
27734561
35.

Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial.

Desportes E, Wagner M, Kamal M, Salomon AV, Deniziaut G, Pierron G, Rouleau E, Jouffroy T, Le Tourneau C, Paoletti X, Servois V.

Oncotarget. 2017 Jan 3;8(1):1760-1773. doi: 10.18632/oncotarget.12051.

36.

Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma.

Guillot-Delost M, Guilleré L, Berger F, Ventre A, Michea P, Sirven P, Pattarini L, Scholer-Dahirel A, Kebir FZ, Huerre M, Chouchane-Mlik O, Lappartient E, Rodriguez J, Jouffroy T, Klijanienko J, Nicolas A, Sastre-Garau X, Honorio S, Mosseri V, Le Peltier N, Sablin MP, Le Tourneau C, Tartour É, Badoual C, Soumelis V.

Oncoimmunology. 2016 Jun 7;5(7):e1179414. doi: 10.1080/2162402X.2016.1179414. eCollection 2016 Jul.

37.

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.

Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C.

Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098.

38.

Antibody drug conjugates: the future of chemotherapy?

Borcoman E, Le Tourneau C.

Curr Opin Oncol. 2016 Sep;28(5):429-36. doi: 10.1097/CCO.0000000000000310. Review.

PMID:
27366963
39.

Cytological features of NUT midline carcinoma arising in sino-nasal tract and parotid gland: Report of two new cases and review of the literature.

Klijanienko J, Le Tourneau C, Rodriguez J, Caly M, Theocharis S.

Diagn Cytopathol. 2016 Sep;44(9):753-6. doi: 10.1002/dc.23506. Epub 2016 Jun 24. Review.

PMID:
27338676
40.

Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.

Sablin MP, Dubot C, Klijanienko J, Vacher S, Ouafi L, Chemlali W, Caly M, Sastre-Garau X, Lappartient E, Mariani O, Rodriguez J, Jouffroy T, Girod A, Calugaru V, Hoffmann C, Lidereau R, Berger F, Kamal M, Bieche I, Le Tourneau C.

Oncotarget. 2016 Jul 26;7(30):47418-47430. doi: 10.18632/oncotarget.10163.

41.

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.

Le Tourneau C, Dreno B, Kirova Y, Grob JJ, Jouary T, Dutriaux C, Thomas L, Lebbé C, Mortier L, Saiag P, Avril MF, Maubec E, Joly P, Bey P, Cosset JM, Sun JS, Asselain B, Devun F, Marty ME, Dutreix M.

Br J Cancer. 2016 May 24;114(11):1199-205. doi: 10.1038/bjc.2016.120. Epub 2016 May 3.

42.

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.

Diéras V, Bachelot T, Campone M, Isambert N, Joly F, Le Tourneau C, Cassier P, Bompas E, Fumoleau P, Noal S, Orsini C, Jimenez M, Imbs DC, Chatelut E.

Oncol Ther. 2016;4(2):211-223. doi: 10.1007/s40487-016-0027-x. Epub 2016 Aug 18.

43.

Precision medicine: lessons learned from the SHIVA trial - Authors' reply.

Le Tourneau C, Belin L, Paoletti X, Bièche I, Kamal M.

Lancet Oncol. 2015 Dec;16(16):e581-2. doi: 10.1016/S1470-2045(15)00455-6. No abstract available.

PMID:
26678200
44.

Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis.

Wassef M, Rodilla V, Teissandier A, Zeitouni B, Gruel N, Sadacca B, Irondelle M, Charruel M, Ducos B, Michaud A, Caron M, Marangoni E, Chavrier P, Le Tourneau C, Kamal M, Pasmant E, Vidaud M, Servant N, Reyal F, Meseure D, Vincent-Salomon A, Fre S, Margueron R.

Genes Dev. 2015 Dec 15;29(24):2547-62. doi: 10.1101/gad.269522.115. Epub 2015 Dec 4.

45.

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.

Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, Rouleau E, Vincent-Salomon A, Servant N, Alt M, Rouzier R, Paoletti X, Delattre O, Bièche I.

J Natl Cancer Inst. 2015 Nov 23;108(4). doi: 10.1093/jnci/djv362. Print 2016 Apr. Review.

46.

Design and statistical principles of the SHIVA trial.

Paoletti X, Asselain B, Kamal M, Servant N, Huppé P, Bieche I, Le Tourneau C.

Chin Clin Oncol. 2015 Sep;4(3):32. doi: 10.3978/j.issn.2304-3865.2015.02.02. Review.

47.

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

Marous M, Bièche I, Paoletti X, Alt M, Razak AR, Stathis A, Kamal M, Le Tourneau C.

Ann Oncol. 2015 Dec;26(12):2419-28. doi: 10.1093/annonc/mdv378. Epub 2015 Sep 14. Review.

PMID:
26371283
48.

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators.

Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.

PMID:
26342236
49.

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D.

Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.

PMID:
26179200
50.

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials.

Paoletti X, Ezzalfani M, Le Tourneau C.

Ann Oncol. 2015 Sep;26(9):1808-12. doi: 10.1093/annonc/mdv266. Epub 2015 Jun 18. Review.

Supplemental Content

Loading ...
Support Center